Concepts (281)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 33 | 2023 | 120 | 7.440 |
Why?
|
| Sarcoma | 15 | 2023 | 149 | 2.610 |
Why?
|
| Bone Substitutes | 9 | 2017 | 27 | 2.170 |
Why?
|
| Soft Tissue Neoplasms | 7 | 2022 | 59 | 1.810 |
Why?
|
| Bone Transplantation | 8 | 2017 | 234 | 1.680 |
Why?
|
| Giant Cell Tumor of Bone | 5 | 2022 | 15 | 1.650 |
Why?
|
| Sarcoma, Ewing | 3 | 2020 | 7 | 1.480 |
Why?
|
| Calcium Sulfate | 6 | 2012 | 20 | 1.110 |
Why?
|
| Musculoskeletal Diseases | 2 | 2015 | 44 | 0.960 |
Why?
|
| Limb Salvage | 5 | 2023 | 11 | 0.940 |
Why?
|
| Humans | 61 | 2023 | 31070 | 0.850 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2023 | 230 | 0.830 |
Why?
|
| Retrospective Studies | 27 | 2023 | 3665 | 0.820 |
Why?
|
| Hip Joint | 2 | 2016 | 406 | 0.770 |
Why?
|
| Leiomyosarcoma | 1 | 2021 | 21 | 0.740 |
Why?
|
| Young Adult | 13 | 2021 | 2063 | 0.730 |
Why?
|
| Adolescent | 16 | 2021 | 2403 | 0.730 |
Why?
|
| Adult | 24 | 2022 | 8949 | 0.720 |
Why?
|
| Osteosarcoma | 8 | 2021 | 35 | 0.720 |
Why?
|
| Calcium Phosphates | 2 | 2012 | 27 | 0.700 |
Why?
|
| Child | 13 | 2021 | 1431 | 0.690 |
Why?
|
| Fractures, Bone | 2 | 2012 | 81 | 0.660 |
Why?
|
| Bone Cysts | 2 | 2016 | 2 | 0.660 |
Why?
|
| Synovitis, Pigmented Villonodular | 2 | 2016 | 2 | 0.660 |
Why?
|
| Child, Preschool | 9 | 2021 | 691 | 0.650 |
Why?
|
| Tibia | 2 | 2010 | 274 | 0.620 |
Why?
|
| Treatment Outcome | 16 | 2023 | 3809 | 0.570 |
Why?
|
| Chondromatosis, Synovial | 1 | 2016 | 3 | 0.560 |
Why?
|
| Male | 26 | 2021 | 16499 | 0.550 |
Why?
|
| Bone Diseases | 2 | 2017 | 24 | 0.550 |
Why?
|
| Internal Fixators | 1 | 2016 | 53 | 0.540 |
Why?
|
| Foot | 1 | 2016 | 32 | 0.540 |
Why?
|
| Arthrodesis | 2 | 2014 | 45 | 0.530 |
Why?
|
| Middle Aged | 21 | 2021 | 10239 | 0.530 |
Why?
|
| Acetabulum | 3 | 2016 | 203 | 0.530 |
Why?
|
| Arthroplasty, Replacement, Knee | 5 | 2022 | 688 | 0.530 |
Why?
|
| Foreign Bodies | 1 | 2016 | 28 | 0.530 |
Why?
|
| Radiotherapy | 1 | 2016 | 54 | 0.520 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 45 | 0.520 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 70 | 0.510 |
Why?
|
| Female | 23 | 2021 | 17018 | 0.500 |
Why?
|
| Radius | 2 | 2014 | 32 | 0.500 |
Why?
|
| Tobramycin | 2 | 2005 | 10 | 0.460 |
Why?
|
| Knee Prosthesis | 2 | 2008 | 240 | 0.450 |
Why?
|
| Survival Rate | 5 | 2021 | 407 | 0.450 |
Why?
|
| Biopsy | 6 | 2023 | 249 | 0.420 |
Why?
|
| Arthralgia | 2 | 2011 | 133 | 0.420 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2010 | 41 | 0.410 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 420 | 0.400 |
Why?
|
| Chondrosarcoma | 4 | 2023 | 37 | 0.400 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 387 | 0.390 |
Why?
|
| Prognosis | 8 | 2023 | 924 | 0.380 |
Why?
|
| Histiocytosis, Sinus | 1 | 2011 | 3 | 0.380 |
Why?
|
| Talus | 1 | 2011 | 12 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 54 | 0.380 |
Why?
|
| Allografts | 4 | 2021 | 202 | 0.380 |
Why?
|
| Edema | 1 | 2011 | 40 | 0.370 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 1935 | 0.360 |
Why?
|
| Patellar Ligament | 1 | 2010 | 56 | 0.360 |
Why?
|
| Humerus | 3 | 2005 | 103 | 0.350 |
Why?
|
| Prosthesis Failure | 4 | 2022 | 539 | 0.330 |
Why?
|
| Osteomyelitis | 3 | 2005 | 23 | 0.330 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 691 | 0.320 |
Why?
|
| Debridement | 3 | 2016 | 105 | 0.320 |
Why?
|
| Femur | 4 | 2022 | 402 | 0.320 |
Why?
|
| Bone Plates | 1 | 2008 | 64 | 0.300 |
Why?
|
| Reoperation | 6 | 2022 | 952 | 0.290 |
Why?
|
| Neoadjuvant Therapy | 5 | 2022 | 78 | 0.280 |
Why?
|
| Cisplatin | 3 | 2017 | 95 | 0.280 |
Why?
|
| Osteogenesis | 1 | 2007 | 107 | 0.270 |
Why?
|
| Aged | 12 | 2021 | 10079 | 0.270 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2022 | 860 | 0.250 |
Why?
|
| Curettage | 3 | 2022 | 8 | 0.250 |
Why?
|
| Orthopedic Procedures | 3 | 2004 | 329 | 0.240 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 208 | 0.240 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 79 | 0.240 |
Why?
|
| Immunohistochemistry | 4 | 2011 | 430 | 0.240 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 5192 | 0.230 |
Why?
|
| Transplantation, Homologous | 2 | 2004 | 296 | 0.230 |
Why?
|
| Margins of Excision | 2 | 2022 | 27 | 0.230 |
Why?
|
| Infant | 3 | 2021 | 578 | 0.230 |
Why?
|
| Pelvic Bones | 1 | 2004 | 20 | 0.230 |
Why?
|
| Joint Instability | 1 | 2008 | 405 | 0.230 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 104 | 0.230 |
Why?
|
| Spinal Neoplasms | 1 | 2023 | 41 | 0.220 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 41 | 0.220 |
Why?
|
| Knee Joint | 2 | 2008 | 826 | 0.210 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 69 | 0.210 |
Why?
|
| Injections | 2 | 2016 | 59 | 0.210 |
Why?
|
| Plasma Gases | 1 | 2022 | 2 | 0.210 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 404 | 0.210 |
Why?
|
| Prostheses and Implants | 2 | 2015 | 170 | 0.210 |
Why?
|
| Neutrophils | 1 | 2023 | 120 | 0.210 |
Why?
|
| Absorbable Implants | 1 | 2002 | 26 | 0.200 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 11 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2015 | 818 | 0.200 |
Why?
|
| Infant, Newborn | 2 | 2021 | 637 | 0.200 |
Why?
|
| Vancomycin | 1 | 2002 | 59 | 0.200 |
Why?
|
| Bone Cements | 3 | 2022 | 95 | 0.200 |
Why?
|
| Apoptosis | 5 | 2022 | 260 | 0.200 |
Why?
|
| Radiography | 5 | 2015 | 695 | 0.190 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 9 | 0.190 |
Why?
|
| Myxosarcoma | 1 | 2020 | 3 | 0.180 |
Why?
|
| Hemipelvectomy | 1 | 2020 | 2 | 0.180 |
Why?
|
| Fibrosarcoma | 1 | 2020 | 9 | 0.180 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 5 | 0.180 |
Why?
|
| Orthopedics | 1 | 2002 | 128 | 0.180 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 21 | 0.170 |
Why?
|
| Hip Prosthesis | 2 | 2022 | 578 | 0.170 |
Why?
|
| Prosthesis-Related Infections | 1 | 2022 | 222 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2016 | 7 | 0.160 |
Why?
|
| Cell Line, Tumor | 7 | 2017 | 272 | 0.160 |
Why?
|
| Medically Underserved Area | 1 | 2019 | 15 | 0.160 |
Why?
|
| Dogs | 4 | 2007 | 264 | 0.160 |
Why?
|
| Medical Oncology | 1 | 2019 | 39 | 0.160 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 73 | 0.160 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 260 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2010 | 99 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 91 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 109 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 86 | 0.150 |
Why?
|
| Osteoarthritis | 1 | 2022 | 384 | 0.150 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 4 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 57 | 0.150 |
Why?
|
| Imidazoles | 1 | 2017 | 73 | 0.140 |
Why?
|
| Ceramics | 1 | 2016 | 25 | 0.140 |
Why?
|
| Piperazines | 1 | 2017 | 91 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 337 | 0.140 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2016 | 10 | 0.140 |
Why?
|
| Synovectomy | 1 | 2016 | 4 | 0.130 |
Why?
|
| Chondroma | 3 | 2012 | 5 | 0.130 |
Why?
|
| Biocompatible Materials | 1 | 2016 | 104 | 0.130 |
Why?
|
| Child Development | 1 | 2016 | 71 | 0.130 |
Why?
|
| Femoral Neoplasms | 1 | 2015 | 4 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2021 | 2045 | 0.120 |
Why?
|
| Supination | 1 | 2014 | 20 | 0.120 |
Why?
|
| Disease Management | 1 | 2016 | 126 | 0.120 |
Why?
|
| Radiotherapy Dosage | 1 | 2015 | 119 | 0.120 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 35 | 0.120 |
Why?
|
| Ossification, Heterotopic | 1 | 2015 | 41 | 0.120 |
Why?
|
| Prosthesis Design | 3 | 2022 | 507 | 0.120 |
Why?
|
| Arthroplasty | 1 | 2016 | 141 | 0.120 |
Why?
|
| Time Factors | 3 | 2022 | 1681 | 0.120 |
Why?
|
| Lung | 1 | 2015 | 173 | 0.120 |
Why?
|
| Hand Strength | 1 | 2014 | 62 | 0.120 |
Why?
|
| Wrist Joint | 1 | 2014 | 63 | 0.120 |
Why?
|
| Drug Implants | 2 | 2005 | 11 | 0.120 |
Why?
|
| Protein Kinases | 1 | 2014 | 15 | 0.110 |
Why?
|
| Cartilage, Articular | 2 | 2016 | 550 | 0.110 |
Why?
|
| Telomerase | 2 | 2004 | 10 | 0.110 |
Why?
|
| Risk Factors | 2 | 2022 | 2593 | 0.110 |
Why?
|
| Receptors, Notch | 1 | 2013 | 1 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2014 | 112 | 0.110 |
Why?
|
| Wnt Proteins | 1 | 2013 | 15 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2011 | 1314 | 0.110 |
Why?
|
| Spinal Fusion | 1 | 2020 | 562 | 0.110 |
Why?
|
| Recovery of Function | 2 | 2012 | 298 | 0.100 |
Why?
|
| Bone Matrix | 2 | 2003 | 28 | 0.100 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2012 | 4 | 0.100 |
Why?
|
| Injections, Intralesional | 1 | 2012 | 29 | 0.100 |
Why?
|
| beta Catenin | 1 | 2013 | 50 | 0.100 |
Why?
|
| Bone Regeneration | 2 | 2003 | 76 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 408 | 0.100 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 35 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 46 | 0.100 |
Why?
|
| Range of Motion, Articular | 1 | 2014 | 736 | 0.090 |
Why?
|
| Ankle | 1 | 2011 | 17 | 0.090 |
Why?
|
| Thoracoscopy | 1 | 2010 | 20 | 0.090 |
Why?
|
| Ilium | 1 | 2010 | 34 | 0.090 |
Why?
|
| Animals | 5 | 2007 | 4724 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 370 | 0.090 |
Why?
|
| Age Factors | 2 | 2019 | 874 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 551 | 0.080 |
Why?
|
| Chicago | 1 | 2012 | 943 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2008 | 322 | 0.070 |
Why?
|
| Compressive Strength | 1 | 2007 | 29 | 0.070 |
Why?
|
| Elasticity | 1 | 2007 | 40 | 0.070 |
Why?
|
| Illinois | 1 | 2008 | 267 | 0.070 |
Why?
|
| Cell Division | 3 | 2022 | 113 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2006 | 32 | 0.070 |
Why?
|
| Radiation Tolerance | 1 | 2006 | 7 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2023 | 1898 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 24 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 107 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2006 | 59 | 0.070 |
Why?
|
| Proteins | 1 | 2006 | 73 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2006 | 103 | 0.070 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2017 | 14 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2016 | 164 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 344 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 443 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 87 | 0.060 |
Why?
|
| Blastomycosis | 1 | 2004 | 17 | 0.060 |
Why?
|
| Lower Extremity | 1 | 2023 | 40 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 105 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2023 | 54 | 0.060 |
Why?
|
| Arthroscopy | 1 | 2011 | 892 | 0.060 |
Why?
|
| Bone Demineralization Technique | 1 | 2003 | 3 | 0.060 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 18 | 0.060 |
Why?
|
| Lymphocyte Count | 1 | 2023 | 35 | 0.060 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 67 | 0.050 |
Why?
|
| Mutation | 2 | 2021 | 409 | 0.050 |
Why?
|
| Exoribonucleases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 13 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2002 | 10 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2023 | 111 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2023 | 144 | 0.050 |
Why?
|
| Necrosis | 1 | 2022 | 32 | 0.050 |
Why?
|
| Bone Resorption | 1 | 2003 | 97 | 0.050 |
Why?
|
| Replantation | 1 | 2022 | 9 | 0.050 |
Why?
|
| Transplantation Immunology | 1 | 2002 | 4 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 39 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2021 | 8 | 0.050 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2002 | 18 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2016 | 498 | 0.050 |
Why?
|
| Forecasting | 1 | 2002 | 115 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 37 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 44 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 60 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 98 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 57 | 0.050 |
Why?
|
| SEER Program | 1 | 2021 | 41 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2004 | 718 | 0.050 |
Why?
|
| Cartilage | 1 | 2002 | 159 | 0.050 |
Why?
|
| DNA Damage | 2 | 2014 | 31 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2002 | 534 | 0.040 |
Why?
|
| Tendons | 1 | 2002 | 229 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2002 | 699 | 0.040 |
Why?
|
| Mesna | 1 | 2019 | 3 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2014 | 113 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 3 | 2004 | 149 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2019 | 14 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 7 | 0.040 |
Why?
|
| Leg | 1 | 2019 | 51 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 70 | 0.040 |
Why?
|
| Arm | 1 | 2019 | 82 | 0.040 |
Why?
|
| Pyrazines | 1 | 2017 | 13 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2017 | 66 | 0.040 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 7 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 190 | 0.030 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 6 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 34 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 43 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 66 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2013 | 9 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1992 | 24 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1992 | 131 | 0.020 |
Why?
|
| Proteoglycans | 1 | 1992 | 345 | 0.020 |
Why?
|
| Acridine Orange | 1 | 2006 | 1 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 11 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2006 | 16 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 57 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2006 | 113 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 80 | 0.020 |
Why?
|
| Cell Survival | 1 | 2006 | 164 | 0.020 |
Why?
|
| Manubrium | 1 | 2004 | 2 | 0.010 |
Why?
|
| Sternoclavicular Joint | 1 | 2004 | 6 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 130 | 0.010 |
Why?
|
| Chondrocytes | 1 | 2004 | 208 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 28 | 0.010 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2002 | 6 | 0.010 |
Why?
|
| Telomere | 1 | 2002 | 7 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2004 | 217 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 60 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 134 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 275 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 329 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 782 | 0.010 |
Why?
|
| Sepharose | 1 | 1992 | 5 | 0.010 |
Why?
|
| Glucuronic Acid | 1 | 1992 | 9 | 0.010 |
Why?
|
| Hexuronic Acids | 1 | 1992 | 10 | 0.010 |
Why?
|
| Alginates | 1 | 1992 | 10 | 0.010 |
Why?
|
| Gels | 1 | 1992 | 12 | 0.010 |
Why?
|
| Keratan Sulfate | 1 | 1992 | 27 | 0.010 |
Why?
|
| Microspheres | 1 | 1992 | 40 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1992 | 111 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1992 | 75 | 0.010 |
Why?
|
| Cattle | 1 | 1992 | 219 | 0.010 |
Why?
|
| Aggrecans | 1 | 1992 | 157 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1992 | 686 | 0.010 |
Why?
|